Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial

Video abstract: View a video abstract for this article.

[1]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[2]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention , 2016, Atherosclerosis.

[3]  C. Le May,et al.  Role of PCSK9 beyond liver involvement , 2015, Current opinion in lipidology.

[4]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[5]  Cholesterol Treatment Trialists' Collaborators.  Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis , 2008, The Lancet.

[6]  B. Zinman,et al.  Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. , 2014, Circulation.

[7]  Szilard Voros,et al.  Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. , 2016, The New England journal of medicine.

[8]  J. Mckenney,et al.  National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. , 2015, Journal of clinical lipidology.

[9]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[10]  Lawrence A Leiter,et al.  Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. , 2017, Diabetes & metabolism.

[11]  A. Mooradian.  Dyslipidemia in type 2 diabetes mellitus , 2009, Nature Clinical Practice Endocrinology &Metabolism.

[12]  Robert O'Neill,et al.  MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets , 2009, Journal of biopharmaceutical statistics.

[13]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[14]  Lawrence A Leiter,et al.  Persistent lipid abnormalities in statin‐treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[15]  C. Cannon,et al.  Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia , 2016, Coronary artery disease.

[16]  M. Krempf,et al.  Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. , 2011, Atherosclerosis.

[17]  K. Kotseva,et al.  EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[18]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[19]  Lawrence A Leiter,et al.  ALIROCUMAB SAFETY IN INDIVIDUALS WITH AND WITHOUT DIABETES MELLITUS: POOLED DATA FROM 14 ODYSSEY TRIALS , 2017 .

[20]  Lawrence A Leiter,et al.  Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[21]  F. Cosentino,et al.  The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[22]  Jennifer G. Robinson,et al.  No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies , 2016, European heart journal.

[23]  D. Gaudet,et al.  Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. , 2016, International journal of cardiology.

[24]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[25]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[26]  H. Ginsberg,et al.  Diabetes and dyslipidemia. , 2001, Heart failure monitor.

[27]  Albert Torri,et al.  Antidrug Antibodies in Patients Treated with Alirocumab. , 2017, The New England journal of medicine.

[28]  B. Cariou,et al.  Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. , 2015, Clinical therapeutics.

[29]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[30]  Lawrence A Leiter,et al.  Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub‐analysis of ODYSSEY COMBO II , 2017, Diabetes, obesity & metabolism.

[31]  Jennifer G. Robinson,et al.  Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. , 2016, The American journal of cardiology.

[32]  J. Spertus,et al.  Psychometric Evaluation of a Treatment Acceptance Measure for Use in Patients Receiving Treatment via Subcutaneous Injection. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[33]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[34]  Deepak L. Bhatt,et al.  Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. , 2014, American heart journal.

[35]  R. Holman,et al.  Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome , 2017, Diabetes, obesity & metabolism.

[36]  R. Little,et al.  The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.

[37]  B. Zinman,et al.  Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the , 2014 .

[38]  Jennifer G. Robinson,et al.  Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. , 2016, The lancet. Diabetes & endocrinology.

[39]  Sara M. Willems,et al.  Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. , 2016, JAMA.

[40]  N. Wong,et al.  Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010. , 2015, Journal of clinical lipidology.

[41]  P. Toth.  Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .

[42]  Hynek Pikhart,et al.  PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study , 2017, The lancet. Diabetes & endocrinology.

[43]  Dylan L. Steen,et al.  RECURRENT CARDIOVASCULAR EVENT RATES IN A CONTEMPORARY COHORT OF 829,498 ADULTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE , 2017 .

[44]  Michel Krempf,et al.  PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. , 2009, Biochemical and biophysical research communications.